Log in
NASDAQ:RDNT

RadNet Stock Forecast, Price & News

$14.52
+0.46 (+3.27 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$13.49
Now: $14.52
$14.67
50-Day Range
$13.94
MA: $15.86
$17.81
52-Week Range
$5.81
Now: $14.52
$23.45
Volume224,705 shs
Average Volume371,699 shs
Market Capitalization$748.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Read More
RadNet logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDNT
CUSIPN/A
Phone310-478-7808

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.15 billion
Cash Flow$3.06 per share
Book Value$4.63 per share

Profitability

Net Income$14.76 million

Miscellaneous

Employees8,498
Market Cap$748.87 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$14.52
+0.46 (+3.27 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











RadNet (NASDAQ:RDNT) Frequently Asked Questions

How has RadNet's stock been impacted by Coronavirus?

RadNet's stock was trading at $17.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RDNT stock has decreased by 15.7% and is now trading at $14.52.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of RadNet?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for RadNet
.

When is RadNet's next earnings date?

RadNet is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for RadNet
.

How were RadNet's earnings last quarter?

RadNet Inc. (NASDAQ:RDNT) released its quarterly earnings data on Monday, August, 10th. The medical research company reported ($0.16) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.44) by $0.28. The medical research company earned $190.60 million during the quarter, compared to analyst estimates of $190.58 million. RadNet had a negative return on equity of 4.28% and a negative net margin of 1.25%. The business's revenue for the quarter was down 34.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.12 EPS.
View RadNet's earnings history
.

What price target have analysts set for RDNT?

2 Wall Street analysts have issued 1 year target prices for RadNet's shares. Their forecasts range from $22.00 to $23.00. On average, they anticipate RadNet's stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 55.0% from the stock's current price.
View analysts' price targets for RadNet
.

Are investors shorting RadNet?

RadNet saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 1,320,000 shares, an increase of 33.7% from the July 30th total of 987,600 shares. Based on an average daily trading volume, of 285,100 shares, the short-interest ratio is currently 4.6 days. Approximately 3.1% of the company's shares are sold short.
View RadNet's Short Interest
.

Who are some of RadNet's key competitors?

What other stocks do shareholders of RadNet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Opko Health (OPK), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Boeing (BA), Rigel Pharmaceuticals (RIGL), UnitedHealth Group (UNH), Alibaba Group (BABA) and NeoGenomics (NEO).

Who are RadNet's key executives?

RadNet's management team includes the following people:
  • Dr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 73)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 48)
  • Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 63)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 58)
  • Mr. Ranjan Jayanathan, Chief Information Officer & GM of Radiology Information Technology Division

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

Who are RadNet's major shareholders?

RadNet's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.03%), Beck Mack & Oliver LLC (3.82%), Dalton Greiner Hartman Maher & Co. (1.98%), Silvercrest Asset Management Group LLC (1.90%), FMR LLC (1.88%) and Russell Investments Group Ltd. (0.89%). Company insiders that own RadNet stock include B Kaplan Survivor's Tru Karen, David L Swartz, John V Crues, Mark Stolper, Michael L Md Sherman, Michael N Murdock and Norman R Hames.
View institutional ownership trends for RadNet
.

Which major investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Russell Investments Group Ltd., Goldman Sachs Group Inc., Assenagon Asset Management S.A., Silvercrest Asset Management Group LLC, Prudential Financial Inc., Bank of America Corp DE, and Miracle Mile Advisors LLC. Company insiders that have sold RadNet company stock in the last year include John V Crues, and Norman R Hames.
View insider buying and selling activity for RadNet
.

Which major investors are buying RadNet stock?

RDNT stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., First Trust Advisors LP, Beck Mack & Oliver LLC, Jennison Associates LLC, Two Sigma Advisers LP, Charles Schwab Investment Management Inc., Swiss National Bank, and State of Tennessee Treasury Department.
View insider buying and selling activity for RadNet
.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $14.52.

How big of a company is RadNet?

RadNet has a market capitalization of $748.87 million and generates $1.15 billion in revenue each year. The medical research company earns $14.76 million in net income (profit) each year or $0.29 on an earnings per share basis. RadNet employs 8,498 workers across the globe.

What is RadNet's official website?

The official website for RadNet is www.radnet.com.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.